Current reports
8-K
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
22 Apr 24
8-K
Departure of Directors or Certain Officers
22 Apr 24
8-K
Other Events
16 Apr 24
8-K
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
11 Mar 24
8-K
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
5 Feb 24
8-K
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an
18 Dec 23
8-K
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
11 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
7 Nov 23
Registration and prospectus
424B3
Prospectus supplement
22 Apr 24
424B3
Prospectus supplement
22 Apr 24
424B3
Prospectus supplement
16 Apr 24
424B3
Prospectus supplement
12 Apr 24
S-1
IPO registration
9 Apr 24
S-8
Registration of securities for employees
11 Mar 24
S-8
Registration of securities for employees
7 Nov 23
424B4
Prospectus supplement with pricing info
6 Nov 23
FWP
Free writing prospectus
2 Nov 23
S-1/A
IPO registration (amended)
1 Nov 23
Other
EFFECT
Notice of effectiveness
15 Apr 24
SEC STAFF
SEC staff action: Order
6 Nov 23
EFFECT
Notice of effectiveness
3 Nov 23
CERT
Certification of approval for exchange listing
2 Nov 23
CORRESP
Correspondence with SEC
1 Nov 23
UPLOAD
Letter from SEC
1 Nov 23
CORRESP
Correspondence with SEC
31 Oct 23
CORRESP
Correspondence with SEC
31 Oct 23
CORRESP
Correspondence with SEC
5 Oct 23
SEC STAFF
SEC staff action: Order
19 Sep 23
Ownership
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G
Omega Fund VI, L.P.
14 Feb 24
SC 13G
Lundbeckfond Invest A/S
14 Feb 24
SC 13G
JANUS HENDERSON GROUP PLC
14 Feb 24
SC 13G
D1 Capital Partners L.P.
14 Feb 24
SC 13G
Longitude Capital Partners IV, LLC
13 Feb 24
3
Tai Sandi See
6 Feb 24
4
REINALDO M DIAZ
6 Feb 24
4
Mette Kirstine Agger
6 Feb 24
4
Eric Adler
6 Feb 24